On March 25, Hybribio was invited to participate in a roundtable discussion in the Philippines. The meeting attracted government representatives, healthcare professionals, specialists and industry experts from the Philippines and abroad.

Ms. Carmen Auste, CEO of Cancer Warriors Foundation, vice president of Cancer Coalition Philippines and civil society representative of the Philippine National Integrated Cancer Control Council, Dr. Marvin Basco, Former President of the Philippine Society of Digestive Endoscopy, Dr. Carmencita Padilla, advisor of the Newborn Screening Reference Center of the Philippines and professor of the University of the Philippines (UP), Dr. Ingrid Magnata, Jhpiego Country Program Manager, Dr. Sybil Bravo, Clinical Associate Professor, Department of Obstetrics and Gynecology, UP College of Medicine, and other delegates attended the meeting.

During the meeting, Hybribio and the Department of Health of the Philippines and local medical experts had a deep discussion on local disease screening, prevention and control. Hybribio’s representitive introduced the company’s leading nucleic acid molecular diagnostic solutions, which were highly affirmed and recognized by the experts and scholars. the Hybribio 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, which has obtained the first NMPA certificate for primary cervical cancer screening in China, provides a highly cost-effective screening option for the Philippines. In addition, Hybribio offers a comprehensive cervical cancer HPV molecular diagnostic solution, including HPV 14 high-risk GenoArray Diagnostic Kit, HPV High-risk E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), 21 HPV GenoArray Diagnostic Kit, 23 HPV Genotyping Real-time PCR Kit, and 37 HPV GenoArray Diagnostic Kit, addressing the different clinical diagnostic needs for HPV.

Sexually transmitted infections are common in the Philippines, the majority of infected persons are asymptomatic. Hybribio has developed an 11-in-1 product, STD11 Real-time PCR Kit, which covers 11 types of pathogens. Furthermore, Hybribio is developing STD2 Real-time PCR Kit, TV, GV, CA Vaginitis Panel Real-time PCR Kit, and more to meet the clinical doctors’ needs.

Early cancer detection plays a crucial role in cancer prevention and treatment. Hybribio has developed a series of cancer methylation reagents including cervical cancer, bladder cancer, colorectal cancer and nasopharyngeal carcinoma. These products aim to alleviate the pain and economic burden of patients, and reduce the cancer mortality rate, thus improving the well-being of the whole society.

In the era of precision medicine, Hybribio provides products covering warfarin, statin, clopidogrel, folic acid, and nitroglycerin, providing effective guidance for clinical rational dosing of medicine. In genetic diseases screening and control, Hybribio has successful established the Foshan hearing loss prevention-and-control model and the Meizhou thalassemia prevention-and-control model in China. These successfully genetic disease control models are remarkable and hold significant potential for future genetic control in the Philippines.

Delegate 1: “In the post-pandemic era, there are many testing items that can be performed in PCR laboratories in the Philippines, and Hybribio's nucleic acid molecular testing solution is paving the way for advanced diagnostics.”

Delegate 2: “Eliminating diseases such as cervical cancer requires the active participation of various stakeholders including government, organizations, enterprises and the public. Meanwhile, it encompasses vaccines and screening. “

Delegate 3: “Precision medication can offer accurate guidance for the diagnosis and treatment of patients in clinical practice. “

The roundtable discussion held in the Philippines was a great success. Participation in this event has enabled Hybribio to gain profound insights into the clinical diagnostic needs and future trajectory of healthcare in the Philippines. Hybribio is eager to collaborate with Philippine government agencies and local physicians to advance local screening programs. By harnessing the power of state-of-the-art molecular diagnostic technologies, we aim to protect the health of women and children in the Philippines and contribute to the creation of a healthier nation. Together, we can make a difference!